INTERNATIONAL FINANCE FACILITY FOR IMMUNISATION COMPANY financials
INTERNATIONAL FINANCE FACILITY FOR IMMUNISATION COMPANY
549300ILK2NRULX3HX87 | Line item | 2021 | 2020 | 2019 |
|---|---|---|---|
| Income statement | |||
| Revenue | $719.8M | $1.35B | — |
| Operating expenses | $1.45B | $214.6M | — |
| Operating profit (EBIT) | -$733.4M | $1.13B | — |
| Profit for the year | -$678.4M | $1.18B | — |
| Total comprehensive income | -$678.4M | $1.18B | — |
| Cash flow statement | |||
| Net cash from operating activities | -$826.8M | -$311.8M | — |
| Net cash from investing activities | -$124.3M | -$46.1M | — |
| Net cash from financing activities | $949.6M | $368.9M | — |
| Net change in cash | -$1.5M | $11.1M | — |
| Balance sheet | |||
| Non-current assets | $3.03B | $2.96B | $1.75B |
| Current assets | $1.17B | $897.2M | $756.6M |
| Cash & equivalents | $11.7M | $13.9M | $15.0K |
| Total equity | $1.61B | $2.29B | $1.11B |
| Non-current liabilities | $2.09B | $1.36B | $830.6M |
| Current liabilities | $497.8M | $207.6M | $559.1M |
| Derived metrics | |||
| Operating margin | -101.9% | 84.1% | — |
| Net margin | -94.3% | 87.5% | — |
| Return on equity | -42.0% | 51.4% | — |
| Cash conversion ratio | 1.22× | -0.26× | — |
| Other reported items | |||
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | $211.2M | $112.0M | — |
| Adjustments For Increase Decrease In Other Operating Payables | -$71.0K | -$344.0K | — |
| Adjustments For Interest Expense | $7.9M | $4.1M | — |
| Adjustments For Interest Income | $667.0K | $4.5M | — |
| Assets Less Current Liabilities | $3.70B | $3.65B | $1.94B |
| Current Assets Liabilities | $672.7M | $689.6M | $197.5M |
| Current Bonds Issued and Current Portion of Noncurrent Bonds Issued | $98.5M | $40.0M | $331.5M |
| Current Derivative Financial Assets | $502.0K | $0 | $190.0K |
| Current Derivative Financial Liabilities | $2.2M | $5.6M | $26.2M |
| Current Prepayments | $294.0K | $32.0K | $0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -$715.0K | $2.8M | — |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -$1.4M | $2.7M | — |
| Interest Expense On Bonds | $7.9M | $4.1M | — |
| Interest Paid Classified As Financing Activities | $6.0M | $4.8M | — |
| Interest Received Classified As Investing Activities | $667.0K | $4.5M | — |
| Investment Income | $667.0K | $4.5M | — |
| Net Assets Liabilities | $1.61B | $2.29B | $1.11B |
| Noncurrent Derivative Financial Assets | $150.1M | $79.4M | $1.9M |
| Noncurrent Derivative Financial Liabilities | $344.4M | $481.0M | $495.2M |
| Noncurrent Portion of Noncurrent Bonds Issued | $1.75B | $876.4M | $178.3M |
| Other Comprehensive Income | $0 | $0 | — |
| Other Current Payables | $960.0K | $1.0M | $1.5M |
| Other Finance Cost | $2.1M | $559.0K | — |
| Proceeds From Issue of Bonds Notes and Debentures | $993.1M | $698.8M | — |
| Repayments of Bonds Notes and Debentures | $37.6M | $325.0M | — |
| Revenue and Operating Income | $720.7M | $1.35B | — |
| Trade and Other Current Receivables Due From Related Parties | $0 | $11.0K | $111.0K |
Every line item above is a fact tagged in INTERNATIONAL FINANCE FACILITY FOR IMMUNISATION COMPANY's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.